<DOC>
	<DOCNO>NCT00732160</DOCNO>
	<brief_summary>Determine effect aldosterone body handle glucose ( sugar ) .</brief_summary>
	<brief_title>Aldosterone Glucose Homeostasis</brief_title>
	<detailed_description>Determine effect aldosterone glucose metabolism human .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<criteria>1 . Ambulatory subject , 18 70 year age , inclusive 2 . For female subject , follow condition must meet : postmenopausal status least 1 year , b statuspost surgical sterilization , c childbearing potential , utilization adequate birth control willingness undergo urine betahcg test prior drug treatment every study day 3 . Metabolic Syndrome define presence &gt; 3 following : Systolic Blood Pressure &gt; 130 mm Hg OR Diastolic Blood Pressure &gt; 85 mm Hg . b Glucose Intolerance ( Fasting Plasma Glucose &gt; 100 mg/dL ) c Increased triglyceride level &gt; 150mg/dL ( 1.7mmol/L ) Decreased level HDL cholesterol For male , less 40 mg/dL For female , less 50 mg/dL e Waist circumference For male , great 40 inch ( 102 cm ) For female , great 35 inch ( 89 cm ) . 1 . Previously diagnose Type I Diabetes , use antidiabetic medication . Subjects type II diabetes medication allow participate fasting blood glucose &lt; 200mg/dL . 2 . Prior allergy medication use study protocol ( e.g . Larginine , potassium chloride ) . 3 . Screening plasma potassium &lt; 3.5 mmol/L use chronic potassium supplement treatment hypokalemia 4 . Use hormone replacement therapy 5 . If statin therapy hypercholesterolemia , change dose within past 6 month . 6 . Breastfeeding 7 . Cardiovascular disease prior myocardial infarction , presence angina pectoris , significant arrhythmia , congestive heart failure ( LV hypertrophy acceptable ) , deep vein thrombosis , pulmonary embolism , second third degree heart block , mitral valve stenosis , aortic stenosis hypertrophic cardiomyopathy 8 . Treatment anticoagulants 9 . History serious neurologic disease cerebral hemorrhage , stroke , seizure , transient ischemic attack 10 . History presence immunological hematological disorder 11 . Diagnosis asthma require use inhale beta agonist &gt; 1 time per week 12 . Clinically significant gastrointestinal impairment could interfere drug absorption 13 . Impaired hepatic function [ aspartate amino transaminase ( AST ) and/or alanine amino transaminase ( ALT ) &gt; 2.0 x upper limit normal range ] 14 . Impaired renal function [ estimate glomerular filtration rate ( eGFR ) &lt; 60ml/min ] determine fourvariable Modification Diet Renal Disease ( MDRD ) equation , serum creatinine ( Scr ) express mg/dl age year : 15. eGFR &lt; 60 ml/min 16 . Hematocrit &lt; 35 % 17 . Any underlying acute disease require regular medication could possibly pose threat subject make implementation protocol interpretation study result difficult , arthritis treat nonsteroidal antiinflammatory drug 18 . Treatment chronic systemic glucocorticoid therapy ( 7 consecutive day 1 month ) 19 . Treatment lithium salt 20 . History alcohol drug abuse 21 . Treatment investigational drug 1 month precede study 22 . Mental condition render subject unable understand nature , scope possible consequence study 23 . Inability comply protocol , e.g. , uncooperative attitude , inability return followup visit , unlikelihood completing study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Glucose</keyword>
	<keyword>Insulin</keyword>
</DOC>